Posted by Michael Wonder on 10 Nov 2020
Health Canada approves Maviret 8 week treatment duration for treatment naïve patients with genotype 3 compensated cirrhosis
10 November 2020 - Maviret (glecaprevir/pibrentasvir) is the only 8 week oral treatment approved for all hepatitis C virus genotypes.
AbbVie announced today that Health Canada has approved a label change for Maviret (glecaprevir/pibrentasvir tablets) to include treatment naïve genotype 3 patients with compensated cirrhosis.
With this change, the recommended treatment duration for all individuals with chronic hepatitis C virus infection who are treatment naïve, genotypes 1-6 with/or without compensated cirrhosis is 8 weeks.
